Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 3/2015

01.05.2015 | Invited Review

Chronic kidney disease and bone metabolism

verfasst von: Junichiro James Kazama, Koji Matsuo, Yoshiko Iwasaki, Masafumi Fukagawa

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Chronic kidney disease-related mineral and bone disease (CKD-MBD) is a syndrome defined as a systemic mineral metabolic disorder associated with CKD, and the term renal osteodystrophy indicates a pathomorphological concept of bone lesions associated with CKD-MBD. Cortical bone thinning, abnormalities in bone turnover and primary/secondary mineralization, elevated levels of circulating sclerostin, increased apoptosis in osteoblasts and osteocytes, disturbance of the coupling phenomenon, iatrogenic factors, accumulated micro-crackles, crystal/collagen disorientation, and chemical modification of collagen crosslinks are all possible candidates found in CKD that could promote osteopenia and/or bone fragility. Some of above factors are the consequences of abnormal systemic mineral metabolism but for others it seem unlikely. We have used the term uremic osteoporosis to describe the uremia-induced bone fragility which is not derived from abnormal systemic mineral metabolism. Interestingly, the disease aspect of uremic osteoporosis appears to be similar to that of senile osteoporosis.
Literatur
1.
Zurück zum Zitat Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, Kestenbaum BR, Stehman-Breen C (2000) Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288:3014–3301CrossRef Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, Kestenbaum BR, Stehman-Breen C (2000) Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288:3014–3301CrossRef
2.
Zurück zum Zitat Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Narita I (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31:315–321CrossRefPubMed Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Narita I (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31:315–321CrossRefPubMed
3.
Zurück zum Zitat Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396–399CrossRefPubMed Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396–399CrossRefPubMed
4.
Zurück zum Zitat Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO) (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945–1953CrossRefPubMed Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO) (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945–1953CrossRefPubMed
5.
6.
Zurück zum Zitat Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int 3:446–450CrossRef Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int 3:446–450CrossRef
7.
Zurück zum Zitat Yamashita T, Yoshioka M, Itoh N (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494–498CrossRefPubMed Yamashita T, Yoshioka M, Itoh N (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494–498CrossRefPubMed
8.
Zurück zum Zitat Fukumoto S, Yamashita T (2001) Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets/osteomalacia. Endocr J 48:603–610CrossRefPubMed Fukumoto S, Yamashita T (2001) Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets/osteomalacia. Endocr J 48:603–610CrossRefPubMed
9.
Zurück zum Zitat Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y (2010) Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 5:1268–1276CrossRefPubMedCentralPubMed Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y (2010) Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 5:1268–1276CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378CrossRefPubMedCentralPubMed Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Quarles LD (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 8:276–286CrossRefPubMed Quarles LD (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 8:276–286CrossRefPubMed
12.
Zurück zum Zitat Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8:819–823CrossRefPubMedCentralPubMed Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8:819–823CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Fukagawa M, Kazama JJ, Kurokawa K (2002) Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant 17:2–5CrossRefPubMed Fukagawa M, Kazama JJ, Kurokawa K (2002) Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant 17:2–5CrossRefPubMed
14.
Zurück zum Zitat Stubbs J, Liu S, Quarles LD (2007) Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 20:302–308CrossRefPubMed Stubbs J, Liu S, Quarles LD (2007) Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 20:302–308CrossRefPubMed
15.
Zurück zum Zitat Koizumi M, Komaba H, Fukagawa M (2013) Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis. Contrib Nephrol 180:110–123CrossRefPubMed Koizumi M, Komaba H, Fukagawa M (2013) Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis. Contrib Nephrol 180:110–123CrossRefPubMed
16.
Zurück zum Zitat Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M (2006) Insufficiency of PTH action on bone in uremia. Kidney Int pp S34–S36 Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M (2006) Insufficiency of PTH action on bone in uremia. Kidney Int pp S34–S36
17.
Zurück zum Zitat Fukagawa M, Kazama JJ, Shigematsu T (2001) Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. Am J Kidney Dis 38:S152–S155CrossRefPubMed Fukagawa M, Kazama JJ, Shigematsu T (2001) Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. Am J Kidney Dis 38:S152–S155CrossRefPubMed
18.
Zurück zum Zitat Frazão JM, Martins P (2009) Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens 18:303–307CrossRefPubMed Frazão JM, Martins P (2009) Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens 18:303–307CrossRefPubMed
19.
Zurück zum Zitat Lomashvili KA, Wang X, O’Neill WC (2014) Role of local versus systemic vitamin D receptors in vascular calcification. Arterioscler Thromb Vasc Biol 34:146–151CrossRefPubMed Lomashvili KA, Wang X, O’Neill WC (2014) Role of local versus systemic vitamin D receptors in vascular calcification. Arterioscler Thromb Vasc Biol 34:146–151CrossRefPubMed
20.
Zurück zum Zitat Tanaka H, Komaba H, Koizumi M, Kakuta T, Fukagawa M (2012) Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder. J Ren Nutr 22:98–101CrossRefPubMed Tanaka H, Komaba H, Koizumi M, Kakuta T, Fukagawa M (2012) Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder. J Ren Nutr 22:98–101CrossRefPubMed
21.
Zurück zum Zitat Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, Matsushima M, Nakayama M, Hosoya T, Era S (2004) Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 66:1988–1993CrossRefPubMed Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, Matsushima M, Nakayama M, Hosoya T, Era S (2004) Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 66:1988–1993CrossRefPubMed
22.
Zurück zum Zitat Iwasaki Y, Kazama JJ, Yamato H, Fukagawa M (2011) Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 48:1260–1267CrossRefPubMed Iwasaki Y, Kazama JJ, Yamato H, Fukagawa M (2011) Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 48:1260–1267CrossRefPubMed
23.
Zurück zum Zitat Iwasaki Y, Kazama JJ, Yamato H, Shimoda H, Fukagawa M (2013) Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. Bone 57:477–483CrossRefPubMed Iwasaki Y, Kazama JJ, Yamato H, Shimoda H, Fukagawa M (2013) Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. Bone 57:477–483CrossRefPubMed
24.
Zurück zum Zitat Yamamoto S, Kazama JJ, Narita I, Naiki H, Gejyo F (2009) Recent progress in understanding dialysis-related amyloidosis. Bone 45:S39–S42CrossRefPubMed Yamamoto S, Kazama JJ, Narita I, Naiki H, Gejyo F (2009) Recent progress in understanding dialysis-related amyloidosis. Bone 45:S39–S42CrossRefPubMed
25.
Zurück zum Zitat Kazama JJ, Yamamoto S, Takahashi N, Ito Y, Maruyama H, Narita I, Gejyo F (2006) Abeta-2 M-amyloidosis and related bone diseases. J Bone Miner Metab 24:182–184CrossRefPubMed Kazama JJ, Yamamoto S, Takahashi N, Ito Y, Maruyama H, Narita I, Gejyo F (2006) Abeta-2 M-amyloidosis and related bone diseases. J Bone Miner Metab 24:182–184CrossRefPubMed
26.
Zurück zum Zitat Kazama JJ, Maruyama H, Gejyo F (2001) Osteoclastogenesis and osteoclast activation in dialysis-related amyloid osteopathy. Am J Kidney Dis 38:S156–S160CrossRefPubMed Kazama JJ, Maruyama H, Gejyo F (2001) Osteoclastogenesis and osteoclast activation in dialysis-related amyloid osteopathy. Am J Kidney Dis 38:S156–S160CrossRefPubMed
27.
Zurück zum Zitat Aggarwal HK, Jain D, Yadav S, Kaverappa V (2013) Bone mineral density in patients with predialysis chronic kidney disease. Ren Fail 35:1105–1111CrossRefPubMed Aggarwal HK, Jain D, Yadav S, Kaverappa V (2013) Bone mineral density in patients with predialysis chronic kidney disease. Ren Fail 35:1105–1111CrossRefPubMed
28.
Zurück zum Zitat Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084–1093CrossRefPubMed Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084–1093CrossRefPubMed
29.
Zurück zum Zitat Sprague SM, Josephson MA (2004) Bone disease after kidney transplantation. Semin Nephrol 24:82–90CrossRefPubMed Sprague SM, Josephson MA (2004) Bone disease after kidney transplantation. Semin Nephrol 24:82–90CrossRefPubMed
30.
Zurück zum Zitat Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD (1991) Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544–550CrossRefPubMed Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD (1991) Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544–550CrossRefPubMed
31.
Zurück zum Zitat Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ (1996) Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 28:515–522CrossRefPubMed Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ (1996) Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 28:515–522CrossRefPubMed
32.
Zurück zum Zitat Westeel FP, Mazouz H, Ezaitouni F, Hottelart C, Ivan C, Fardellone P, Brazier M, El Esper I, Petit J, Achard JM, Pruna A, Fournier A (2000) Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int 58:1788–1796CrossRefPubMed Westeel FP, Mazouz H, Ezaitouni F, Hottelart C, Ivan C, Fardellone P, Brazier M, El Esper I, Petit J, Achard JM, Pruna A, Fournier A (2000) Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int 58:1788–1796CrossRefPubMed
33.
Zurück zum Zitat Seibel MJ, Cooper MS, Zhou H (2013) Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 1:59–70CrossRefPubMed Seibel MJ, Cooper MS, Zhou H (2013) Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 1:59–70CrossRefPubMed
34.
Zurück zum Zitat Tamler R, Epstein S (2006) Nonsteroid immune modulators and bone disease. Ann N Y Acad Sci 1068:284–296CrossRefPubMed Tamler R, Epstein S (2006) Nonsteroid immune modulators and bone disease. Ann N Y Acad Sci 1068:284–296CrossRefPubMed
35.
Zurück zum Zitat Westenfeld R, Schlieper G, Wöltje M, Gawlik A, Brandenburg V, Rutkowski P, Floege J, Jahnen-Dechent W, Ketteler M (2011) Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis–implications for post-transplantation bone disease. Nephrol Dial Transplant 26:4115–4123CrossRefPubMed Westenfeld R, Schlieper G, Wöltje M, Gawlik A, Brandenburg V, Rutkowski P, Floege J, Jahnen-Dechent W, Ketteler M (2011) Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis–implications for post-transplantation bone disease. Nephrol Dial Transplant 26:4115–4123CrossRefPubMed
36.
Zurück zum Zitat Meng Y, Zhang H, Li Y, Li Q, Zuo L (2014) Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats. Bone 58:168–176CrossRefPubMed Meng Y, Zhang H, Li Y, Li Q, Zuo L (2014) Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats. Bone 58:168–176CrossRefPubMed
37.
Zurück zum Zitat Jamal SA, West SL, Miller PD (2012) Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 23:1191–1198CrossRefPubMed Jamal SA, West SL, Miller PD (2012) Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 23:1191–1198CrossRefPubMed
38.
Zurück zum Zitat Yenchek RH, Ix JH, Shlipak MG, Bauer DC, Rianon NJ, Kritchevsky SB, Harris TB, Newman AB, Cauley JA, Fried LF, Health, Aging, and Body Composition Study (2012) Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7:1130–1136CrossRefPubMedCentralPubMed Yenchek RH, Ix JH, Shlipak MG, Bauer DC, Rianon NJ, Kritchevsky SB, Harris TB, Newman AB, Cauley JA, Fried LF, Health, Aging, and Body Composition Study (2012) Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7:1130–1136CrossRefPubMedCentralPubMed
39.
Zurück zum Zitat Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients–a single-center cohort study. Nephrol Dial Transplant 27:345–351CrossRefPubMed Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients–a single-center cohort study. Nephrol Dial Transplant 27:345–351CrossRefPubMed
40.
Zurück zum Zitat Amerling R, Harbord NB, Pullman J, Feinfeld DA (2010) Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif 29:293–299CrossRefPubMed Amerling R, Harbord NB, Pullman J, Feinfeld DA (2010) Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif 29:293–299CrossRefPubMed
41.
Zurück zum Zitat Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20:186–190CrossRefPubMed Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20:186–190CrossRefPubMed
42.
Zurück zum Zitat Hernández E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, Martinis R, Bellorin-Font E, Weisinger JR (2003) Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63:2269–2274CrossRefPubMed Hernández E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, Martinis R, Bellorin-Font E, Weisinger JR (2003) Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63:2269–2274CrossRefPubMed
43.
Zurück zum Zitat Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829–1835CrossRefPubMed Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829–1835CrossRefPubMed
44.
Zurück zum Zitat McCormick BB, Davis J, Burns KD (2012) Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 60:626–628CrossRefPubMed McCormick BB, Davis J, Burns KD (2012) Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 60:626–628CrossRefPubMed
45.
Zurück zum Zitat Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC, Tsai R, Fujimoto G, Nakagomi M, Tsubouchi H, Rosenberg E, Uchida S (2014) Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis–a double-blind, randomized, dose-finding study. Osteoporos Int 25:367–376CrossRefPubMed Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC, Tsai R, Fujimoto G, Nakagomi M, Tsubouchi H, Rosenberg E, Uchida S (2014) Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis–a double-blind, randomized, dose-finding study. Osteoporos Int 25:367–376CrossRefPubMed
46.
Zurück zum Zitat McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420CrossRefPubMed McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420CrossRefPubMed
47.
Zurück zum Zitat Kazama JJ, Yamamoto S, Narita I, Kurihara S (2011) Nuclear chromatin-concentrated osteoblasts in renal bone diseases. Ther Apher Dial 15:9–13CrossRefPubMed Kazama JJ, Yamamoto S, Narita I, Kurihara S (2011) Nuclear chromatin-concentrated osteoblasts in renal bone diseases. Ther Apher Dial 15:9–13CrossRefPubMed
48.
Zurück zum Zitat Ballanti P, Coen G, Mazzaferro S, Taggi F, Giustini M, Calabria S, Ferrannini M, Bonucci E (2001) Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate. Histopathology 38:571–583CrossRefPubMed Ballanti P, Coen G, Mazzaferro S, Taggi F, Giustini M, Calabria S, Ferrannini M, Bonucci E (2001) Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate. Histopathology 38:571–583CrossRefPubMed
49.
Zurück zum Zitat Kazama JJ (2011) Bone histology in chronic kidney disease-related mineral and bone disorder. Ther Apher Dial 15:23–25CrossRefPubMed Kazama JJ (2011) Bone histology in chronic kidney disease-related mineral and bone disorder. Ther Apher Dial 15:23–25CrossRefPubMed
50.
Zurück zum Zitat Quarles LD, Lobaugh B, Murphy G (1992) Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145–150PubMed Quarles LD, Lobaugh B, Murphy G (1992) Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145–150PubMed
51.
Zurück zum Zitat Gal-Moscovici A, Popovtzer MM (2005) New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 63:284–289CrossRefPubMed Gal-Moscovici A, Popovtzer MM (2005) New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 63:284–289CrossRefPubMed
53.
Zurück zum Zitat Cournot-Witmer G, Zingraff J, Plachot JJ, Escaig F, Lefèvre R, Boumati P, Bourdeau A, Garabédian M, Galle P, Bourdon R, Drüeke T, Balsan S (1981) Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization. Kidney Int 20:375–378CrossRefPubMed Cournot-Witmer G, Zingraff J, Plachot JJ, Escaig F, Lefèvre R, Boumati P, Bourdeau A, Garabédian M, Galle P, Bourdon R, Drüeke T, Balsan S (1981) Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization. Kidney Int 20:375–378CrossRefPubMed
54.
Zurück zum Zitat McCarthy JT, Hodgson SF, Fairbanks VF, Moyer TP (1991) Clinical and histologic features of iron-related bone disease in dialysis patients. Am J Kidney Dis 17:551–561CrossRefPubMed McCarthy JT, Hodgson SF, Fairbanks VF, Moyer TP (1991) Clinical and histologic features of iron-related bone disease in dialysis patients. Am J Kidney Dis 17:551–561CrossRefPubMed
55.
Zurück zum Zitat Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26:1368–1376CrossRefPubMedCentralPubMed Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26:1368–1376CrossRefPubMedCentralPubMed
56.
Zurück zum Zitat Saito M, Fujii K, Soshi S, Tanaka T (2006) Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17:986–995CrossRefPubMed Saito M, Fujii K, Soshi S, Tanaka T (2006) Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17:986–995CrossRefPubMed
57.
Zurück zum Zitat Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T (2008) Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab 26:93–100CrossRefPubMed Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T (2008) Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab 26:93–100CrossRefPubMed
58.
59.
Zurück zum Zitat Mitome J, Yamamoto H, Saito M, Yokoyama K, Marumo K, Hosoya T (2011) Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 88:521–529CrossRefPubMed Mitome J, Yamamoto H, Saito M, Yokoyama K, Marumo K, Hosoya T (2011) Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 88:521–529CrossRefPubMed
60.
Zurück zum Zitat Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS (2000) Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58:2200–2205CrossRefPubMed Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS (2000) Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58:2200–2205CrossRefPubMed
61.
Zurück zum Zitat Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 70:1358–1366CrossRefPubMed Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 70:1358–1366CrossRefPubMed
62.
Zurück zum Zitat Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM (2006) PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47:149–156CrossRefPubMed Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM (2006) PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47:149–156CrossRefPubMed
63.
Zurück zum Zitat Glorieux G, Schepers E, Pletinck A, Dhondt A, Vanholder R (2013) Review of protein-bound toxins, possibility for blood purification therapy. Blood Purif 35:45–50CrossRefPubMed Glorieux G, Schepers E, Pletinck A, Dhondt A, Vanholder R (2013) Review of protein-bound toxins, possibility for blood purification therapy. Blood Purif 35:45–50CrossRefPubMed
66.
Zurück zum Zitat Stenvinkel P, Larsson TE (2013) Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis 62:339–351CrossRefPubMed Stenvinkel P, Larsson TE (2013) Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis 62:339–351CrossRefPubMed
Metadaten
Titel
Chronic kidney disease and bone metabolism
verfasst von
Junichiro James Kazama
Koji Matsuo
Yoshiko Iwasaki
Masafumi Fukagawa
Publikationsdatum
01.05.2015
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 3/2015
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-014-0639-x

Weitere Artikel der Ausgabe 3/2015

Journal of Bone and Mineral Metabolism 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.